NVCR

SEC source: 0001562180-25-001831 · primarydocument.xml · nonDerivative · entry 2

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,791

F2 · price: On February 27, 2025, the reporting person sold 267 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001831 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,058

F1 · price: On February 27, 2025, the reporting person sold 1,379 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001916 · primarydocument.xml · nonDerivative · entry 2

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,399

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: On February 27, 2025, the reporting person sold 1,808 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001916 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,207

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On February 27, 2025, the reporting person sold 9,345 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001915 · primarydocument.xml · nonDerivative · entry 2

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,970

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: On February 27, 2025, the reporting person sold 1,989 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001915 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,959

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On February 27, 2025, the reporting person sold 10,277 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001914 · primarydocument.xml · nonDerivative · entry 2

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,706

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: On February 27, 2025, the reporting person sold 225 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001914 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,931

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On February 27, 2025, the reporting person sold 1,162 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001913 · primarydocument.xml · nonDerivative · entry 2

Leupin Nicolas · CIK 0002007766 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,133

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: On the transaction date, the reporting person sold 161 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001913 · primarydocument.xml · nonDerivative · entry 1

Leupin Nicolas · CIK 0002007766 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,294

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: On February 27, 2025, the reporting person sold 830 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001836 · primarydocument.xml · nonDerivative · entry 2

Leupin Nicolas · CIK 0002007766 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,133

F2 · price: On February 27, 2025, the reporting person sold 161 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001836 · primarydocument.xml · nonDerivative · entry 1

Leupin Nicolas · CIK 0002007766 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,294

F1 · price: On February 27, 2025, the reporting person sold 830 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001835 · primarydocument.xml · nonDerivative · entry 2

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,706

F2 · price: On February 27, 2025, the reporting person sold 225 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001835 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,931

F1 · price: On February 27, 2025, the reporting person sold 1,162 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001834 · primarydocument.xml · nonDerivative · entry 2

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,970

F2 · price: On February 27, 2025, the reporting person sold 1,989 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001834 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,959

F1 · price: On February 27, 2025, the reporting person sold 10,277 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001833 · primarydocument.xml · nonDerivative · entry 2

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,399

F2 · price: On February 27, 2025, the reporting person sold 1,808 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-001833 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,207

F1 · price: On February 27, 2025, the reporting person sold 9,345 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-000375 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,437

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $26.44 USD to $27.185 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-25-000065 · primarydocument.xml · nonDerivative · entry 2

Danziger Asaf · CIK 0001654435 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 415,640

F3 · shares: Represents restricted share units that are scheduled to vest in equal installments on December 31, 2025 and December 31, 2026, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-25-000067 · primarydocument.xml · nonDerivative · entry 1

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,721

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024.

SEC source: 0001562180-25-000066 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,552

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024.

SEC source: 0001562180-25-000065 · primarydocument.xml · nonDerivative · entry 1

Danziger Asaf · CIK 0001654435 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,640

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024.

SEC source: 0001562180-24-007567 · primarydocument.xml · derivative · entry 3

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,620

Underlying: Ordinary Shares · 45,620 shares

Expires 2034-11-03

F3 · derivative.exercise_date: Options to buy 45,620 ordinary shares will vest in equal installments on each of November 4, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-007567 · primarydocument.xml · nonDerivative · entry 2

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,597

F2 · shares: Represents restricted share units that are scheduled to vest in equal parts on November 4, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

SEC source: 0001562180-24-007567 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,459

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-24-007515 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,503

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.80 USD to $15.94 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-24-007516 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,236

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.88 USD to $15.9603 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-24-007517 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,093

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.48 USD to $16.01 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001562180-24-005984 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,179

F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0001562180-24-006042 · primarydocument.xml · nonDerivative · entry 1

GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,290

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.

SEC source: 0001562180-24-006043 · primarydocument.xml · nonDerivative · entry 1

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,052

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.

SEC source: 0001562180-24-006041 · primarydocument.xml · nonDerivative · entry 1

Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,228

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.

SEC source: 0001562180-24-006040 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,465

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.

SEC source: 0001562180-24-006039 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,834

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.

SEC source: 0001562180-24-006038 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,903

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.

SEC source: 0001562180-24-004765 · primarydocument.xml · derivative · entry 2

Stafford Kristin · CIK 0001970438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F2 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004765 · primarydocument.xml · nonDerivative · entry 1

Stafford Kristin · CIK 0001970438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,053

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004776 · primarydocument.xml · derivative · entry 2

Ocean Allyson J · CIK 0001967326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F2 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004776 · primarydocument.xml · nonDerivative · entry 1

Ocean Allyson J · CIK 0001967326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,053

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004774 · primarydocument.xml · derivative · entry 2

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F3 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004774 · primarydocument.xml · nonDerivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,673

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

F2 · balance_after: Report no longer includes indirect ownership of shares held by filer's adult child. Child no longer shares a residence with the filer.

SEC source: 0001562180-24-004768 · primarydocument.xml · derivative · entry 2

Hung David · CIK 0001310880 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F2 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004768 · primarydocument.xml · nonDerivative · entry 1

Hung David · CIK 0001310880 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,194

F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004761 · primarydocument.xml · derivative · entry 3

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F3 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004761 · primarydocument.xml · nonDerivative · entry 2

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,850

F2 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004759 · primarydocument.xml · derivative · entry 3

Scannell Timothy J · CIK 0001451533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F3 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004759 · primarydocument.xml · nonDerivative · entry 2

Scannell Timothy J · CIK 0001451533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,981

F2 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004758 · primarydocument.xml · derivative · entry 3

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,229

Underlying: Ordinary Shares · 6,229 shares

Expires 2034-06-04

F3 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.

SEC source: 0001562180-24-004758 · primarydocument.xml · nonDerivative · entry 2

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,192

F2 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.